Saturday, July 11, 2026

pharma · Lymphoma of B-cell origin · Malignant Solid Tumors

Genmab

Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lun

Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
Status
Public
HQ
Carl Jacobsens Vej 30, 2500 Valby, DK
Employees
2,847
Programs
29
Drugs
56
Patents
0
Clinical program

tisotumab vedotin

Phase 2 · small molecule · Solid Tumor

tisotumab vedotin for Solid Tumor is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).

← All Genmab A/S projects Phase 2 small molecule completed

Internal code GCT1015-06

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Genmab A/S
Phase
Phase 2
Modality
small_molecule
Indication
Solid Tumor
Status
completed
Trials
1